Nicox S.A. provided certain regulatory and clinical updates for NCX 470, its novel nitric oxide (NO) donating bimatoprost analog being developed for intraocular pressure (IOP) lowering. Increased IOP is one of the principal risk factors of open-angle glaucoma and ocular hypertension. Nicox held a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) at the end of 2016. Based on the feedback from this meeting, Nicox is finalizing the design of a first-in-human trial for NCX 470 which will be a Phase 2 multi-center, investigator masked, 28-day, parallel group, dose-finding study in adult subjects with elevated IOP due to open-angle glaucoma or ocular hypertension. Multiple doses of NCX 470 will be compared in safety and efficacy to bimatoprost. The primary endpoint of the study is the mean reduction in IOP, and the objective is to identify the appropriate safe and effective dose of NCX 470 to be taken into Phase 3 studies. Recruitment of subjects is expected to begin in early 2018, subject to IND filing and acceptance1, and the study is expected to take approximately 1 year to complete.